Atara Biotherapeutics is a biotechnology company that focuses on developing transformative therapies for patients with serious medical conditions, particularly in the areas of cancer and autoimmune diseases
The company leverages its proprietary platform to create innovative T-cell immunotherapy treatments, which harness the power of the immune system to target and attack disease. Atara's commitment to scientific research and collaboration is aimed at advancing the field of cellular therapies, and it is dedicated to improving the lives of patients by addressing unmet medical needs through its cutting-edge therapeutic solutions.
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQFDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.
